A new study finds women who suffer from migraines with aura are at a higher risk for cardiovascular disease (CVD) including heart attacks, strokes and blood clots and the risks significantly increase for those taking supplemental hormones.
Results of the study show that women who have migraines and who take hormones including hormonal contraceptives and HRT have high risk of blood clots. "This risk for clots, such as deep vein thrombosis, has been associated with all women taking hormonal contraceptives, but it is found to be more prevalent in women with migraine," researchers noted.
With all these risks, women with migraines should be very cautious and pay close attention to warnings regarding the use of hormone therapy and find alternatives that do not have these risks. Many women are under the false conception that bio-identical hormones don't carry the same risks.
Lyle Henry of Tuliv Migraine Research, one of the leading migraine prevention providers, has found in multiple studies that hormone based contraceptives (i.e. BC pills, patches, shots and inserts) as well as supplemental hormones used in HRT, can also be major contributors to the incident of migraine for women. Simply put, hormones trigger migraines, no matter what their source.
Today more women are turning away from hormones and moving to products like Tuliv Hormonal Peace to treat the symptoms of menopause because it does not add hormones to the body.
Tuliv Hormonal Peace is designed to work naturally in the body to manage the way the body reacts to hormonal changes in order to relieve the symptoms of menopause. To learn more about how Tuliv Hormonal Peace is helping women, see More About Menopause and HRT alternative.
Tuliv Migraine Defense is the leading non-prescription treatment for the prevention of migraines. To learn more about migraine prevention with Tuliv Migraine Defense, see http://www.tuliv.com
Don't ignore the risks of taking hormones if you are prone to migraines - consider the safe alternatives provided by Tuliv Wellness Products.
No comments:
Post a Comment